key: cord-0740104-5fn1nfpf authors: Wu, Lin; O'Kane, Aislinn M.; Peng, Hu; Bi, Yaguang; Motriuk-Smith, Dagmara; Ren, Jun title: SARS-CoV-2 and Cardiovascular Complications: from Molecular Mechanisms to Pharmaceutical Management date: 2020-06-21 journal: Biochem Pharmacol DOI: 10.1016/j.bcp.2020.114114 sha: 9c3cfbcd1be08047f60d90b682ce29a061b0dbc5 doc_id: 740104 cord_uid: 5fn1nfpf The coronavirus disease 2019 (COVID-19), elicited by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is a pandemic public health emergency of global concern. Other than the profound severe pulmonary damage, SARS-CoV-2 infection also leads to a series of cardiovascular abnormalities, including myocardial injury, myocarditis and pericarditis, arrhythmia and cardiac arrest, cardiomyopathy, heart failure, cardiogenic shock, and coagulation abnormalities. Meanwhile, COVID-19 patients with preexisting cardiovascular diseases are often at a much higher risk of increased morbidity and mortality. Up–to-date, a number of mechanisms have been postulated for COVID-19-associated cardiovascular damage including SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) activation, cytokine storm, hypoxemia, stress and cardiotoxicity of antiviral drugs. In this context, special attention should be given towards COVID-19 patients with concurrent cardiovascular diseases, and special cardiovascular attention is warranted for treatment of COVID-19. Here we will summarize the relationship between SARS-CoV-2 and cardiovascular diseases, 97 and discuss possible mechanisms of action behind SARS-CoV-2 infection-induced damage to 98 cardiovascular system. Ang II production or indirect inhibition of Ang II through upregulation of ACE2 (Figure 1) . 324 In a multi-centered study involving 1128 COVID-19 patients combined with hypertension, 325 administration of ACE inhibitors or ARBs was associated with a lower mortality rate (3.7% Nowcasting and forecasting the potential domestic and international spread 556 of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study Genomic characterisation and 560 epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding MERS, SARS and other coronaviruses as causes of pneumonia Estimation of the reproductive number of novel coronavirus 565 (COVID-19) and the probable outbreak size on the Diamond Princess cruise ship: A data-driven analysis Clinical evidence does not support corticosteroid treatment for 568 2019-nCoV lung injury Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia 571 in Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Cardiovascular complications of severe acute respiratory syndrome Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus 580 (MERS-CoV): a systematic review and meta-analysis Clinical Characteristics and Outcomes of Patients with Myocardial Infarction, Myocardial Injury, and 583 Nonelevated Troponins China Medical Treatment Expert Group for, Clinical Characteristics of Coronavirus Disease Prevalence and impact of cardiovascular 590 metabolic diseases on COVID-19 in China Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after Infection Association Between Hospitalization for 596 Pneumonia and Subsequent Risk of Cardiovascular Disease Hong Kong Hospital Authority, Corticosteroid 599 treatment of severe acute respiratory syndrome in Hong Kong Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus Remdesivir and 603 chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Myocardial 607 localization of coronavirus in COVID-19 cardiogenic shock Cardiac Involvement in a Patient Coronavirus fulminant myocarditis saved with glucocorticoid and human 612 immunoglobulin Clinical predictors of mortality due to COVID-19 based 614 on an analysis of data of 150 patients from Wuhan Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study Cardiovascular 622 Implications of Fatal Outcomes of Patients With Coronavirus Disease Effectiveness of convalescent plasma therapy in 627 severe COVID-19 patients Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, 630 China: a descriptive study Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan China: a single-centered, retrospective, observational study, The Lancet. Respiratory medicine -hospital cardiac arrest 635 outcomes among patients with COVID-19 pneumonia in Characteristics and Outcomes of 637 21 Critically Ill Patients With COVID-19 in Washington State Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus 641 Disease 2019 (COVID-19) Pandemic Clinical course and risk factors for mortality of adult inpatients with 644 COVID-19 in Wuhan, China: a retrospective cohort study Heart 646 Failure with Preserved Ejection Fraction in a Postpartum Patient with Superimposed Preeclampsia and 647 COVID-19 Epicardial adipose tissue as a metabolic transducer: role in heart 649 failure and coronary artery disease Abnormal coagulation parameters are associated with poor prognosis in 651 patients with novel coronavirus pneumonia Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence Acute pulmonary embolism and COVID-19 pneumonia: a 657 random association? Endothelial cell infection and endotheliitis in COVID-19 Lip, E.b.t.I.N.E. Global Covid-19 Thrombosis Collaborative Group Right Ventricular, COVID-19 and Thrombotic or Thromboembolic Disease: 668 Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review Angiotensin-converting enzyme 2 (ACE2) as a 671 SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target ACE2: from vasopeptidase to SARS virus receptor -7)-forming activity in failing human heart ventricles: evidence for upregulation of the 677 angiotensin-converting enzyme Homologue ACE2 Angiotensin-(1-7) ameliorates myocardial 679 remodeling and interstitial fibrosis in spontaneous hypertension: role of MMPs/TIMPs Counterregulatory actions of 682 angiotensin Angiotensin-converting enzyme 2 is an essential regulator of heart function SARS-coronavirus 688 modulation of myocardial ACE2 expression and inflammation in patients with SARS A pilot 692 clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome Urgent need for evaluating agonists of angiotensin-(1-7)/Mas receptor axis for treating patients 695 with COVID-19, International journal of infectious diseases : IJID : official publication of the International 696 Society for Substituting Angiotensin-(1-7) to Prevent Lung Damage in SARS-CoV-2 Infection? Angiotensin-converting enzyme 2 is a functional receptor for the SARS 701 coronavirus SARS-CoV-2 Cell Entry Depends on ACE2 and 704 TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Impact of angiotensin-converting 706 enzyme inhibitors and statins on viral pneumonia Angiotensin-converting enzyme 2 protects from severe acute lung failure Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized 716 With COVID-19 Association of Renin-Angiotensin System Inhibitors With Severity 718 or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease Statement of the European Society of Hypertension (ESH) on 721 hypertension, Renin Angiotensin System blockers and COVID-19 SARS-CoV-2: a storm is raging Into the eye of the cytokine 725 storm Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome Journal of interferon & cytokine research : 29 730 the official journal of the International Society for Interferon and Toxic Responses of the Immune System Straight-Up Fire Angiotensin II revisited: new roles in inflammation, immunology and 736 aging The Renin-Angiotensin-aldosterone system in 738 vascular inflammation and remodeling Renin-angiotensin-aldosterone system and progression of renal disease Presenting Characteristics, Comorbidities, and 745 Outcomes Among 5700 Patients Hospitalized With COVID-19 in the Care for Critically Ill Patients With COVID-19 Discovering drugs to treat coronavirus disease 2019 (COVID-19) Co-administration of rivaroxaban with drugs that share its elimination 751 pathways: pharmacokinetic effects in healthy subjects Controlled Trial of Ebola Virus Disease Therapeutics Hydroxychloroquine: from malaria to autoimmunity Cardiomyopathy related to antimalarial therapy with illustrative case report The impact of stress on body function: A 767 review Impact of psychological factors on the pathogenesis of 769 cardiovascular disease and implications for therapy Novel coronavirus treatment with ribavirin: Groundwork for 771 an evaluation concerning COVID-19 Remdesivir for severe acute respiratory syndrome coronavirus 2 causing 773 COVID-19: An evaluation of the evidence Learning from the Past: Possible Urgent Prevention and Treatment 775 Options for Severe Acute Respiratory Infections Caused by 2019-nCoV Chloroquine is a potent inhibitor of SARS coronavirus infection and spread Hydroxychloroquine, a less 779 toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro Wolters Kluwer Clinical Drug Information Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta 785 against MERS-CoV Zhonghua 787 Jie He He Hu Xi Za Zhi Adults Hospitalized with Severe Covid-19 On the use of corticosteroids for 2019-nCoV pneumonia University of Minnesota Launches COVID-19 Clinical Trials of Blood Pressure Drug Losartan. 797 University of Minnesota Medical School Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection Clinical 803 characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center 804 study in Wenzhou city Clinical characteristics of 806 140 patients infected with SARS-CoV-2 in Clinical 808 Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study